Lesch O-M
Universitätsklinik für Psychiatrie und Psychotherapie, Medizinische Universität Wien, Währinger Gürtel 18-20, Vienna, Austria.
Fortschr Neurol Psychiatr. 2009 Sep;77(9):507-12. doi: 10.1055/s-0028-1109590. Epub 2009 Jul 30.
Diagnoses are made for identifying rather homogeneous groups of patients being thereby relevant for research and for therapy. Therefore diagnostic manuals, like the DSM-IV and the ICD-10 are subjected to changing knowledge derived from research on one hand and to changes of clinical necessities. The diagnosis of substance related disorders, published for DSM-IV in 1994 and for the ICD-10 in 1992, has proven of value for epidemiological research and economic validation. In spite of these advantages the concept has prove to be too broad and rather unspecific for research, specific therapeutic strategies and for defining an illness course. During the last 20 years research has yielded many criteria of interest, which never entered DSM IV or ICD-10, remaining therefore on the level of single items, which are nowadays additionally assigned to all patients (like e. g. early versus late onset) or on the level of typologies (like e. g. Lesch's typology) demanding different treatments. To give an example: acamprosate has lasting relapse preventing effects in Lesch types I and II, while naltrexone is effective in types III and IV. For rendering an expertise in Germany, the referring literature recommends to utilize Lesch's typology additionally to the ICD-10 diagnosis, especially when prognosis or therapeutic strategies are demanded. Since 1999 different expert groups strive for including new criteria into DSM IV and ICD-10. The revised manuals should include easily assignable items for severity of different arrays (time illness onset, co-morbidity, withdrawal symptoms, bridge symptoms and neurological sequela). Different therapy stages (e. g. withdrawal or relapse prevention) need a different weighting of individual symptoms (e. g. degree of intoxication, severity of withdrawal is needed for acute treatment, while an assignment of co-morbidity and personality factors is necessary for relapse prevention). This quantifier is rendered by Lesch's typology, which is available in the form of a computer programme, based on a decision tree (see also www.ausam.at - Typology according to Lesch). Non substance related disorders should enter other diagnostic categories, like e. g. impulse control disorders. A revised diagnostic classification suggests presently offered therapeutic strategies to follow up with necessary modifications. A tailor made therapy according to subgroups can result in better long term performance of therapies offered to persons suffering form substance related disorders.
诊断的目的是识别出相对同质的患者群体,这对于研究和治疗都具有重要意义。因此,像《精神疾病诊断与统计手册》第四版(DSM-IV)和《国际疾病分类》第十版(ICD-10)这样的诊断手册,一方面要根据研究得出的知识变化进行调整,另一方面也要适应临床需求的变化。1994年为DSM-IV以及1992年为ICD-10发布的物质相关障碍的诊断,已被证明在流行病学研究和经济验证方面具有价值。尽管有这些优点,但事实证明该概念对于研究、特定治疗策略以及确定病程来说过于宽泛且相当不具体。在过去的20年里,研究产生了许多有价值的标准,但这些标准从未被纳入DSM-IV或ICD-10,因此仍停留在单个项目层面,如今这些项目被额外应用于所有患者(例如早发与晚发),或者停留在需要不同治疗方法的类型层面(例如莱施的类型学)。举个例子:阿坎酸对莱施I型和II型有持久的预防复发作用,而纳曲酮对III型和IV型有效。为了在德国提供专业意见,参考文献建议除了ICD-10诊断外,还应采用莱施的类型学,尤其是在需要判断预后或制定治疗策略时。自1999年以来,不同的专家小组一直在努力将新的标准纳入DSM-IV和ICD-10。修订后的手册应包括易于确定的不同类别严重程度的项目(疾病发作时间、共病情况、戒断症状、过渡症状和神经后遗症)。不同的治疗阶段(例如戒断或预防复发)需要对个体症状进行不同的加权(例如中毒程度、急性治疗需要戒断的严重程度,而预防复发则需要考虑共病情况和人格因素)。这种量化由莱施的类型学提供,它以计算机程序的形式呈现,基于决策树(另见www.ausam.at - 莱施类型学)。非物质相关障碍应归入其他诊断类别,例如冲动控制障碍。修订后的诊断分类目前建议对现有的治疗策略进行必要的调整后予以采用。根据亚组进行量身定制的治疗可以使为患有物质相关障碍的人提供的治疗在长期效果上更好。